Dr. David Park, MD
Claim this profileProvidence Medical Foundation
Area of expertise
Pancreatic Cancer
David Park, MD has run 8 trials for Pancreatic Cancer. Some of their research focus areas include:
Lung Cancer
David Park, MD has run 5 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Providence Medical Foundation
Providence St. Jude Medical Center
Clinical Trials David Park, MD is currently running
Supportive Care Models
for Cancer
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Recruiting
1 award
N/A
N-803 + PD-L1 t-haNK + Bevacizumab
for Glioblastoma
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The phase 2B portion is an open-label, randomized study to evaluate the efficacy and safety for the following 2 experimental arms in participants with recurrent or progressive GBM: NAI, bevacizumab, and TTFields combination therapy (Arm A) or NAI, PD-L1 t-haNK, bevacizumab, and TTFields combination therapy (Arm B). Phase 2 Treatment for all enrolled participants will consist of repeated cycles of 28 days for a maximum treatment period of 76 weeks (19 cycles) as follows: Every 2 weeks (Days 1 and 15 of a 28-day cycle) Fourteen (14) participants were enrolled in the phase 2 portion of this study as of the date of this v02 protocol. No additional participants will be administered therapy in phase 2. Phase 2B Participants will be randomized 1:1 to 1 of 2 experimental arms (Arm A or Arm B). Treatment for all enrolled participants will consist of repeated 8-week cycles for a maximum treatment period of up to 80 weeks (10 cycles). Experimental Arm (A): Every 2 weeks (Days 1, 15, 29, and 43 of an 8-week cycle) Up to twenty (20) participants will be randomized in phase 2B (up to 10 participants/arm. Duration of Treatment: Participants will receive study treatment for up to 76 weeks during phase 2 (up to 19 repeated 28-day cycles) and for up to 80 weeks (up to 10 repeated 8-week cycles) during phase 2B or until they report unacceptable toxicity (not corrected with dose reduction), withdraw consent, or if the Investigator feels it is no longer in the participant's best interest to continue treatment. Treatment may also be discontinued if the participant has confirmed PD per iRANO, unless the participant is clinically stable and is considered potentially deriving benefit per Investigator's assessment. Duration of Follow-up: Participants who discontinue study treatment should remain in the study for follow-up. Participants should be followed for collection of survival status, posttreatment therapies (phase 2 and phase 2B), and medical history (phase 2B only) every 12 weeks (± 2 weeks) for the first 2 years then yearly thereafter for an additional 3 years. The maximum duration of follow-up is 5 years (260 weeks).
Recruiting
1 award
Phase 2
4 criteria
More about David Park, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments David Park, MD has experience with
- ExoFlo
- Bevacizumab
- NovoTTF-200T
- NovoTTF-100L(P)
- Nab Paclitaxel
- Gemcitabine
Breakdown of trials David Park, MD has run
Pancreatic Cancer
Lung Cancer
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Park, MD specialize in?
David Park, MD focuses on Pancreatic Cancer and Lung Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is David Park, MD currently recruiting for clinical trials?
Yes, David Park, MD is currently recruiting for 4 clinical trials in Fullerton California. If you're interested in participating, you should apply.
Are there any treatments that David Park, MD has studied deeply?
Yes, David Park, MD has studied treatments such as ExoFlo, Bevacizumab, NovoTTF-200T.
What is the best way to schedule an appointment with David Park, MD?
Apply for one of the trials that David Park, MD is conducting.
What is the office address of David Park, MD?
The office of David Park, MD is located at: Providence Medical Foundation, Fullerton, California 92835 United States. This is the address for their practice at the Providence Medical Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.